Rosetta Genomics has announced plans for a potential sale of its PersonalizeDx business, which markets fluorescence in situ hybridization-based cancer tests as part of its corporate strategy realignment to concentrate on the RosettaGx Reveal microRNA-based thyroid nodule classification assay. The sale "would have the benefit of bringing in nondilutive cash, as well as reducing our cash burn rate by approximately 20 percent," said company President and CEO Kenneth Berlin.
Rosetta Genomics eyes sale of PersonalizeDx business
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.